This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (67)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Alert me on articles by topic

Philomeen M. M. Kuijer, MD, PhD; Barbara A. Hutten, MD; Martin H. Prins, MD, PhD; Harry R. Büller, MD, PhD

Arch Intern Med. 1999;159:457-460.

Objectives  To construct and validate the bleeding risk prediction score, which is based on variables identified in the literature that can be easily obtained before the institution of anticoagulant therapy, in a large independent cohort of patients who were treated with anticoagulant therapy for established venous thromboembolism to allow for quantitative assessment of the risks and benefits of the therapy and to adapt the patient's management accordingly.

Methods  We constructed a bleeding risk prediction score, based on variables and their odds ratios identified in the literature, which can be easily obtained before the institution of anticoagulant therapy (score=[1.6xage]+[1.3xsex]+[2.2xmalignancy]). Subsequently, we evaluated the score in a test group of 241 patients treated with anticoagulant therapy for venous thromboembolism to determine the optimal cutoff points for the prediction of hemorrhagic complications, using receiver operating characteristic curve analysis. We then validated this score in an independent cohort of 780 patients. A score of 3 or more points, 1 to 3 points, or 0 points represented a high, intermediate, or low bleeding risk, respectively.

Results  The score in about one fifth of the patients in the test group was classified as predicting high risk for bleeding complications. The risk of all bleeding complications was 26% in this group and the risk of major bleeding complications was 14%. The area under the curve was 0.75 (95% confidence interval, 0.64-0.84) and 0.82 (95% confidence interval, 0.66-0.98) for all bleeding complications and major bleeding complications, respectively. When validated, there was a moderate loss of predictive power of the score, but the categorization of the patients by the score remained clinically useful; 20% of the patients were classified as high risk, and the bleeding rate was 17% for all bleeding complications and 7% for major bleeding complications compared with 4% and 1%, respectively, in those categorized as low risk.

Conclusions  With the use of 3 easily obtainable, clinical variables in a prediction model, it is possible to identify a subgroup of patients at the start of anticoagulant therapy who have a high risk of developing hemorrhagic complications. Further studies should address whether additional measures to prevent bleeding decrease the bleeding incidence without compromising efficacy.

From the Center for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research (Drs Kuijer and Büller) and the Department of Clinical Epidemiology and Biostatistics (Drs Hutten and Prins), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT | FULL TEXT  

Maintaining Therapeutic Anticoagulation: The Importance of Keeping "Within Range"
Lane and Lip
Chest 2007;131:1277-1279.
FULL TEXT  

A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy
Garcia and Hylek
Evid. Based Med. 2007;12:57-57.
FULL TEXT  

Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema.
Kakar et al.
Chest 2006;130:1296-1299.
FULL TEXT  

Development of a contemporary bleeding risk model for elderly warfarin recipients.
Shireman et al.
Chest 2006;130:1390-1396.
ABSTRACT | FULL TEXT  

Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit
Rothberg et al.
ANN INTERN MED 2005;143:241-250.
ABSTRACT | FULL TEXT  

Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation
Schulman and Beyth
Eur Heart J Suppl 2005;7:C34-C40.
ABSTRACT | FULL TEXT  

Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors
Battistella et al.
Arch Intern Med 2005;165:189-192.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly
Pineo and Hull
CLIN APPL THROMB HEMOST 2005;11:15-23.
ABSTRACT  

Managing Complications of Anticoagulant Therapy
Smythe et al.
Journal of Pharmacy Practice 2004;17:327-346.
ABSTRACT  

Combined Anticoagulant-Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients
Shireman et al.
Stroke 2004;35:2362-2367.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Levine et al.
Chest 2004;126:287S-310S.
ABSTRACT | FULL TEXT  

Long-Term Management of Patients After Venous Thromboembolism
Kearon
Circulation 2004;110:I-10-I-18.
ABSTRACT | FULL TEXT  

The Management of Venous Thromboembolic Disease in Older Adults
Rich
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M34-41.
ABSTRACT | FULL TEXT  

In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage
Scott
Evid. Based Med. 2003;8:85-85.
FULL TEXT  

Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study
Meyer et al.
Arch Intern Med 2002;162:1729-1735.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant Treatment
Levine et al.
Chest 2001;119:108S-121S.
FULL TEXT  

Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy
Douketis et al.
Arch Intern Med 2000;160:3431-3436.
ABSTRACT | FULL TEXT  

Outpatient Treatment of Deep Venous Thrombosis
Carman et al.
Chest 1999;116:1492-1493.
FULL TEXT